Rachik Petrosyan: functionalities of the Informational Analytical System allow to expose overrated prices in drug procurement

07-11-2017 | 15:48

Due to disseminated distorted information about performance of the Informational Analytical System for monitoring and control of medicinal drug procurement (IAS), FAS reports: IAS functionalities already enables to estimate average weighted prices for drug procurement per unit of active substance for a particular International Non-Proprietary Name, thanks to which it is possible to expose overrates prices in the course of drug procurement.

Efficiency of reducing budgetary expenses in procurement, and as a consequence, accuracy of the system work to a great extent depends on unifying information in the State Register of Medicinal Drugs.

“Today we can compare average weighted prices per unit of active substance (for INN) with the price for procurement of a particular drug of a specific trade name and dosage, set by the ordering party in the course of drug procurement, and fix overrated prices for particular procurement with regard to the average weighted price. The problem is that to prove overrated prices and incriminate the ordering party, it is necessary to determine the equivalency of the procured drug. Until the Ministry of Health Care does not refine the State Register of Medicinal Drugs, and equivalency is not determined, unfair ordering parties have legal justification of the highest prices fro procured drug from those entered in the Register”, emphasized Deputy Head of FAS Rachik Petrosyan. “Adopting the necessary regulatory acts by the Ministry of Health Care will enable, first, to exclude overrated initial prices in advance and, second, ensure real competition between equivalent medicinal drugs and reduce prices in the course of bidding”.



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do Institutional Memory Mission, Goals, Values Priority Setting Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings Global Competition Review Using our website International Cooperation Treaties & Agreements OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 OECD meetings 2019 OECD meetings 2020 OECD meetings 2021 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD 18th session IGE UNCTAD 8th UN Conference on Competition 19th session IGE UNCTAD EEU Model Law on Competition ICN BRICS BRICS Conferences Documents The BRICS Competition Law and Policy Centre (BRICS Competition Centre) BRICS Working Groups for the research of competition issues in socially important markets The Working Group for Research on the Competition Issues in the Pharmaceutical Markets Chair: Russia The Working Group for Research on food value chains Chair: South Africa The Working Group for Research on the Competition Issues in the Automobile Markets Co-chaired: India, South Africa The Working Group for Research on the Competition Issues in the Digital Markets Co-chairs: Brazil, Russia BRICS Coordination Committee on antimonopoly policy EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Document Library Legislation Reports & Analytics Cases & decisions COVID-19 Contacts Give feedback Contact us Links Authorities Worldwide